# Jointown Pharmaceutical Group Jointown Pharmaceutical Group is a Corporate Investor based in Wuhan, China. ## Overview - **Organization type:** Corporate Investor - **Headquarters:** Wuhan, China - **Region:** Asia - **Address:** No. 8 Longyang Avenue, Hanyang District, Wuhan, Hubei, China - **Founded:** 1999 - **Assets under management:** Undisclosed - **Website:** jztey.com - **LinkedIn:** https://www.linkedin.com/company/jointown-pharmaceutical-group - **Wikidata:** Q10878836 ## Regulatory record - **Reports private funds:** No ## About Jointown Pharmaceutical Group launched in 1999 as a private wholesale drug distributor in Wuhan. Founder Liu Baolin, alongside his brothers Liu Zhaonian and Liu Shulin, scaled the business into one of China's top three pharmaceutical distribution networks, competing directly with state-owned giants Sinopharm and China Resources Pharma. The firm went public on the Shanghai Stock Exchange (stock code 600998), with the Liu family's holding vehicle Chuchang Investment Group retaining a 34.6% controlling stake. The firm's investment posture is inseparable from its operating DNA. Jointown deploys capital across three primary asset classes: healthcare logistics infrastructure, commercial real estate, and strategic corporate venturing within the pharmaceutical supply chain. Its Wuhan Logistics Center in Dongxihu District anchors a national network of distribution hubs spanning mainland China. The firm also launched the Jointown Pharmaceutical Warehousing and Logistics REIT, a portfolio of industrial assets that monetizes the physical backbone of its distribution business. In the United States, the firm developed the Jointown International Headquarters in Los Angeles, signaling a direct real estate investment strategy in a major gateway market. Confirmed holdings include the Jointown Building global headquarters in Hanyang District and multiple logistics facilities across Chinese provinces. The group ranks consistently among the Fortune China 500. While total professionals and AUM are not publicly disclosed, the parent entity's balance-sheet heft — derived from distributing Chinese and Western patent medicines, medical devices, and health management services — is the primary funding source for its real asset investments. In a recent operational milestone, the firm listed its pharmaceutical warehousing and logistics REIT portfolio, converting operating real estate into a liquid investment vehicle. Adjacent to its for-profit investment activities, the Liu family controls the Hubei Jointown Charity Foundation, a philanthropic vehicle focused on health and community welfare in its home province. Jointown's structural differentiator is its corporate-investor architecture, which funds real asset acquisitions directly from operating cash flows rather than third-party LP commitments. This model — deploying retained earnings from pharmaceutical distribution into logistics infrastructure and cross-border real estate — creates a flywheel where the operating company underwrites the investment portfolio. The separation of the listed operating entity from the family-controlled holding company, Chuchang Investment Group, provides governance distance while preserving strategic alignment. The foundation adds a third leg, formalizing the family's long-term commitment to Hubei province beyond the commercial lifecycle of the distribution business. ## Sectors - Healthcare Services - Real Estate - Infrastructure - Logistics ## Offices - Los Angeles, California, USA ## People - Liu Baolin — Founder and Honorary President - Liu Zhaonian — Co-founder - Liu Shulin — Co-founder and Vice Chairman Emeritus - Liu Changyun — President and CEO ## Questions ### Who runs investment decisions at Jointown Pharmaceutical Group? Investment decisions flow through the Liu family's holding entity, Chuchang Investment Group, which owns 34.6% of the publicly listed operating company. President and CEO Liu Changyun oversees day-to-day corporate strategy, while Founder Liu Baolin retains influence as Honorary President. The family's direct involvement in real asset allocation distinguishes this structure from an institution with a dedicated CIO. ### How is Jointown's wealth tied to its operating business? The firm's investment capital is generated almost entirely from its pharmaceutical distribution profits. Jointown is one of China's top three drug distributors, a position built by consolidating a fragmented wholesale market. Retained earnings from this operation — not third-party LP commitments — fund the logistics REIT and US commercial real estate acquisitions. ### What real assets does Jointown actually own? Jointown controls a national logistics network in mainland China, anchored by the Wuhan Logistics Center in Dongxihu District. The firm also launched a listed pharmaceutical warehousing and logistics REIT and developed the Jointown International Headquarters, a mixed-use commercial property in Los Angeles. The Jointown Building in Hanyang District serves as the global headquarters. ### What is the Hubei Jointown Charity Foundation, and how is it separated from the business? The foundation is a philanthropic vehicle controlled by the Liu family, focused on health and community initiatives in Hubei province. It operates as a legally separate entity from both the listed Jointown Pharmaceutical Group and the family holding company, providing a formal structure for charitable giving without commingling philanthropic and commercial assets. ## Related profiles - [Joinn Laboratories (China)](https://altss.com/profile/joinn-laboratories-china) - [JoMiJo Foundation](https://altss.com/profile/jomijo-foundation) --- Last updated: 2026-08-10T15:58:45.833Z Canonical page: https://altss.com/profile/jointown-pharmaceutical-group Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology